Company Overview and News

 
Main Street Banks’ New Lending Rivals: Hedge Funds and Private Equity - WSJ

19h wsj
Main Street banks are feeling squeezed by competition from new rivals: nonbanks like hedge funds and private-equity firms that are elbowing into business loans.

 
US Financial 15 Split Corp.: Preferred Dividend Declared

2018-05-18 globenewswire
TORONTO, May 18, 2018 (GLOBE NEWSWIRE) -- US Financial 15 Split Corp ("US Financial 15") declares its monthly distribution of $0.04003 for each Preferred share, or 5.25% annually based on the previous month end net asset value. Distributions are payable June 8, 2018 to shareholders on record as at May 31, 2018.

 
Bank Stocks Will Benefit Greatly From Upcoming Regulatory Changes

2018-05-16 investorplace
As if there wasn’t enough reason to be bullish on them in the shadow of rising interest rates, Bank of America Corp (NYSE:BAC), Citigroup Inc (NYSE:C) and Wells Fargo & Co (NYSE:WFC) — along with all other bank stocks — could soon be enjoying an even stronger tailwind. How so? By the time you’re reading this, the U.S. bank regulations landscape could look considerably different than it has at any time since 2008’s subprime mortgage meltdown.

1
FITB / Fifth Third Bancorp FORM 8-K (Current Report)

2018-05-10 sec.gov
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549

 
Should iShares Morningstar Mid-Cap Value ETF (JKI) Be on Your Investing Radar?

2018-05-10 zacks
If you're interested in broad exposure to the Mid Cap Value segment of the US equity market, look no further than the iShares Morningstar Mid-Cap Value ETF (JKI - Free Report) , a passively managed exchange traded fund launched on 06/28/2004.

3
Bright Lights On Capitalist Woodstock, Tech Developers And Sports Betting

2018-05-05 seekingalpha
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning.

 
FITB / Fifth Third Bancorp FORM 10-Q (Quarterly Report)

2018-05-04 sec.gov
Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

 
Fifth Third CEO Announces Plan to Expand in Tampa Bay Region

2018-05-01 zacks
As part of Fifth Third Bancorp’s (FITB - Free Report) re-evaluation of the branch network, the banking giant is exploring the cities which are underserved, and taking steps to open new branches. Per a bizjournals article, the bank's CEO, Greg D. Carmichael, and Florida regional president — David Call — have planned to open new branches in the Tampa Bay region, in a bid to expand footprint in various key markets.

 
5 Great ETFs for the Second Quarter | InvestorPlace

2018-04-30 investorplace
The first quarter of 2018 wasn’t exactly that wonderful for investors. It started out just fine — driven by rising GDP growth and expectations of the new Republican tax plan … but then things sort of fell out. Volatility returned with a vengeance and the market entered a downward spiral. The benchmark SPDR S&P 500 ETF Trust (NYSEARCA:SPY) dropped 2.64% in March after a 3.89% decline in February. All in all, the SPY managed to lose about 1.

 
As Downtown Booms, Detroit's Suburbs Seek Reinvention - The Atlantic

2018-04-29 citylab
The city is experiencing a sustained real estate boom, poaching employers—even pro sports teams—from surrounding municipalities. Places like Southfield, Pontiac, and Dearborn will have to find ways to keep up.

 
Bank Stock Roundup: STI, RF, FITB & COF Beat Q1 Estimates, WFC to Pay $1B Fine

2018-04-27 zacks
Major banks that reported first-quarter 2018 results over the last five trading days managed to record bottom-line improvement, driven by rising rates, stable asset quality and lower taxes. Apart from the benefits from higher interest rates, banks’ results reflected a slight improvement in lending activities. However, higher expenses and slowdown in mortgage banking business continued to be major headwinds.

 
New York Community Bancorp (NYCB) Q1 Earnings Meet Estimates

2018-04-26 zacks
New York Community Bancorp (NYCB - Free Report) reported first-quarter 2018 earnings per share of 20 cents, in line with the Zacks Consensus Estimate. However, the bottom line compares unfavorably with 23 cents recorded in the prior-year quarter.

 
Tuesday’s Biggest Winners and Losers in the S&P 500

2018-04-24 247wallst
Tuesday was another down day for the broad U.S. markets and another continuation from the overall drop that started last Thursday. Each of the major averages started out the day positive but quickly fell negative, and each closed at least 1.3% lower on the day. Crude oil pulled back for its first time in a while, but $70 is still in sight. The S&P 500 sectors were almost all negative. The most positive sectors were energy and real estate up 0.

 
Fifth Third's (FITB) CEO Greg Carmichael on Q1 2018 Results - Earnings Call Transcript

2018-04-24 seekingalpha
Fifth Third Bancorp (NASDAQ:FITB) Q1 2018 Results Earnings Conference Call April 24, 2018 9:00 AM ET

 
Earnings reports lift stocks; 10-year yield hits 3 percent

2018-04-24 nzherald.co.nz
NEW YORK (AP) — U.S. stocks are higher Tuesday morning as investors applaud strong first-quarter results from companies including machinery maker Caterpillar, appliance maker Whirlpool and Fifth Third Bancorp. Smaller companies made big gains in an optimistic sign for the U.S. economy. Bond yields continue to rise and the 10-year Treasury note reached 3 percent for the first time in more than four years.

Related Articles

TROV: TrovaGene Analysis and Research Report

13m - Asif

BUSINESS TrovaGene is a clinical-stage, precision medicine oncology therapeutics company. The company's primary focus is to develop oncology therapeutics for improved cancer care and to optimize drug development by leveraging its proprietary Precision Cancer Monitoring® (“PCM”) technology in tumor genomics. The company's lead drug candidate, PCM-075, is a Polo-like Kinase 1 (“PLK1”) selective adenosine triphosphate (“ATP”) competitive inhibitor. PCM-075 has shown preclinical antitumor activity as a single agent and synergy in combination with more than ten different chemotherapeutics and targeted therapies, such as Zytiga® (abiraterone acetate), Beleodaq® (belinostat), Quizartinib (AC220), a development stage FLT3 inhibitor, and Velcade® (bortezomib) in Acute Myeloid Leukemia (“AML”), metastatic Castration-Resistant Prostate Cancer (“mCRPC”) and other hematologic and solid tumor cancers. On March 15, 2017, the company announced the licensing of PCM-075, a PLK1 inhibitor...

SGMO: Sangamo BioSciences Analysis and Research Report

2018-05-19 - Asif

OVERVIEW Sangamo BioSciences is a clinical stage biotechnology company focused on translating ground-breaking science into genomic therapies that transform patients’ lives using its industry-leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy. Sangamo BioSciences is a leader in the research and development of zinc finger proteins, or ZFPs, a naturally occurring class of proteins found in humans. Sangamo BioSciences has used its knowledge and expertise to develop a proprietary technology platform in both genome editing and gene regulation. ZFPs can be engineered to make zinc finger nucleases, or ZFNs, proteins that can be used to specifically modify DNA sequences by adding or knocking out specific genes, or genome editing, and ZFP transcription factors or ZFP TFs, proteins that can be used to increase or decrease gene expression, or gene regulation. In the process of developing this platform, Sangamo BioSciences has accrued signific...

HMNY: Helios and Matheson Analytics Analysis and Research Report

2018-05-19 - Asif

Business Overview The company provide high quality information technology, or IT, services and solutions including a range of technology platforms focusing on big data, business intelligence, and consumer-centric technology. More recently, to provide greater value to stockholders, the Company has sought to expand its business primarily through acquisitions that leverage its capabilities and expertise. As of March 31, 2018, the Company owned 81.2%, and as of the date of this report the Company owns 91.8%, of the outstanding shares of MoviePass (excluding outstanding MoviePass options and warrants). MoviePass is the premiere movie theater subscription service in the United States which provides its subscribers the ability to view up to one new movie title per day for one monthly subscription price. The company's more than 2 million subscribers have access to see films in over 91% of U.S movie theaters. By the end of April 2018, the company implemented certain measures ...

CUSIP: 316773100